Severe imported malaria involving hyperparasitemia (≥ 10%) in non-immune children : Assessment of French practices
Copyright © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved..
BACKGROUND: Plasmodium falciparum hyperparasitemia (over or equal to 10%), isolated or associated with other severity criteria, should be managed in a pediatric intensive care unit according to the French pediatric guidelines. The main objective of our study was to describe the management and course of these special cases.
POPULATION AND METHODS: We conducted a retrospective study in eight French hospital facilities from January 2007 to December 2014. We reviewed the management of non-immune children aged 0-15 years, assessing the following: clinical and paraclinical data, type of care unit, treatment initiated, initial and long-term course. Data were analyzed for the whole population and for two groups according to the place of first-line management: group A (in pediatric intensive care unit), and group B (other places).
RESULTS: A total of 61 children were included, 14 (23%) of whom were initially admitted to the intensive care unit (group A), all with neurological or hemodynamic disorders. Only 23 children (38%) overall received intravenous antimalarial treatment and the other patients received exclusively oral treatment. No deaths were reported. Median parasitemia was comparable in the two groups. In group B (n = 47/61, 77%), isolated hyperparasitemia, jaundice, and renal failure were predominant. The children who underwent initial intravenous treatment (n = 5/47, 11%) all progressed favorably, as did 92% of the children who received oral treatment (n = 42/47, 89%).
CONCLUSION: A majority of children with Plasmodium falciparum hyperparasitemia were managed outside the pediatric intensive care unit via the oral route, against the French pediatric guidelines except when neurologic or hemodynamic disorders were present. Initial clinical evaluation and hospital supervision are essential for the best management of these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie - 29(2022), 4 vom: 11. Mai, Seite 300-306 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vasse, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimalarials |
|---|
| Anmerkungen: |
Date Completed 12.05.2022 Date Revised 12.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arcped.2022.01.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338187618 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338187618 | ||
| 003 | DE-627 | ||
| 005 | 20231226000117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arcped.2022.01.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338187618 | ||
| 035 | |a (NLM)35288027 | ||
| 035 | |a (PII)S0929-693X(22)00033-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vasse, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severe imported malaria involving hyperparasitemia (≥ 10%) in non-immune children |b Assessment of French practices |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2022 | ||
| 500 | |a Date Revised 12.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a BACKGROUND: Plasmodium falciparum hyperparasitemia (over or equal to 10%), isolated or associated with other severity criteria, should be managed in a pediatric intensive care unit according to the French pediatric guidelines. The main objective of our study was to describe the management and course of these special cases | ||
| 520 | |a POPULATION AND METHODS: We conducted a retrospective study in eight French hospital facilities from January 2007 to December 2014. We reviewed the management of non-immune children aged 0-15 years, assessing the following: clinical and paraclinical data, type of care unit, treatment initiated, initial and long-term course. Data were analyzed for the whole population and for two groups according to the place of first-line management: group A (in pediatric intensive care unit), and group B (other places) | ||
| 520 | |a RESULTS: A total of 61 children were included, 14 (23%) of whom were initially admitted to the intensive care unit (group A), all with neurological or hemodynamic disorders. Only 23 children (38%) overall received intravenous antimalarial treatment and the other patients received exclusively oral treatment. No deaths were reported. Median parasitemia was comparable in the two groups. In group B (n = 47/61, 77%), isolated hyperparasitemia, jaundice, and renal failure were predominant. The children who underwent initial intravenous treatment (n = 5/47, 11%) all progressed favorably, as did 92% of the children who received oral treatment (n = 42/47, 89%) | ||
| 520 | |a CONCLUSION: A majority of children with Plasmodium falciparum hyperparasitemia were managed outside the pediatric intensive care unit via the oral route, against the French pediatric guidelines except when neurologic or hemodynamic disorders were present. Initial clinical evaluation and hospital supervision are essential for the best management of these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Children | |
| 650 | 4 | |a France | |
| 650 | 4 | |a Imported malaria | |
| 650 | 4 | |a Parasitemia | |
| 650 | 4 | |a Plasmodium falciparum | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 700 | 1 | |a Faye, A |e verfasserin |4 aut | |
| 700 | 1 | |a Naudin, J |e verfasserin |4 aut | |
| 700 | 1 | |a Titomanlio, L |e verfasserin |4 aut | |
| 700 | 1 | |a Angoulvant, A |e verfasserin |4 aut | |
| 700 | 1 | |a Pham, L-L |e verfasserin |4 aut | |
| 700 | 0 | |a French National Specialist Center for Malaria |e verfasserin |4 aut | |
| 700 | 1 | |a Carbajal, R |e verfasserin |4 aut | |
| 700 | 1 | |a de Suremain, N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives de pediatrie : organe officiel de la Societe francaise de pediatrie |d 1994 |g 29(2022), 4 vom: 11. Mai, Seite 300-306 |w (DE-627)NLM074731173 |x 1769-664X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:4 |g day:11 |g month:05 |g pages:300-306 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arcped.2022.01.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 4 |b 11 |c 05 |h 300-306 | ||